Abstract
Background
The overall usefulness of palliative thoracic re-irradiation depends on the balance between efficacy, survival, and toxicity, and is difficult to judge from previous studies. In the absence of patient-reported data, we developed a method for provider decision regret that addresses the question “would we re-irradiate this patient again in light of the known outcome?” Furthermore, we analyzed different reasons for decision regret and defined a subgroup at increased risk.
Patients and methods
A retrospective analysis of 33 patients with lung cancer re-irradiated with 17–45 Gy was performed. Reasons for decision regret included re-irradiation within the last 30 days of life, immediate radiological progression after re-irradiation (as opposed to stable disease or objective response), radiation myelopathy, any grade 4–5 toxicity, grade 3 pneumonitis, and other grade 3 toxicity in the absence of a symptomatic benefit or a time period of at least 3 months without worsening of the treated tumor.
Results
Median survival time was 5.2 months (95% confidence interval 3.4–7.0 months). Symptomatic and radiological responses were observed. Provider decision regret was declared in 12 patients (36%): 2 patients with grade 3 pneumonitis, 3 patients with a short survival (radiotherapy during the last 30 days of life), and 7 patients with progression. Decision regret was declared only in patients with Eastern Cooperative Oncology Group (ECOG) performance status (PS) 2 or 3 and was associated with a time interval to re-irradiation <6 months.
Conclusion
Our data support the usefulness and acceptable side effects profile of palliative re-irradiation for lung cancer. Patients with reduced PS are at increased risk of futile treatment. Future research should aim at prediction of immediate disease progression (the prevailing cause of decision regret). Evaluation of provider decision regret has the potential to improve the way we learn from retrospective databases and should also be considered for other scenarios where high-quality prospective outcome data are lacking.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Nieder C, Langendijk JA, Guckenberger M et al (2017) Preserving the legacy of reirradiation: a narrative review of historical publications. Advances in Radiation Oncology 2:176–182
Green N, Melbye RW (1982) Lung cancer: retreatment of local recurrence after definitive irradiation. Cancer 49:865–868
Nieder C, De Ruysscher D, Gaspar LE et al (2017) Reirradiation of recurrent node-positive non-small cell lung cancer after previous stereotactic radiotherapy for stage I disease: a multi-institutional treatment recommendation. Strahlenther Onkol 193:515–524
Caivano D, Valeriani M, De Matteis S et al (2018) Re-irradiation in lung disease by SBRT: a retrospective, single institutional study. Radiat Oncol 13:87
Horne ZD, Dohopolski MJ, Clump DA et al (2018) Thoracic reirradiation with SBRT for residual/recurrent and new primary NSCLC within or immediately adjacent to a prior high-dose radiation field. Pract Radiat Oncol 8:e117–e123
Nieder C, Langendijk JA, Guckenberger M et al (2016) Prospective randomized clinical studies involving reirradiation: lessons learned. Strahlenther Onkol 192:679–686
Nieder C, Tollåli T, Haukland E et al (2018) A four-tiered prognostic score for patients receiving palliative thoracic radiotherapy for lung cancer. Cancer Invest 36:59–65
Nieder C, Grosu AL, Andratschke NH et al (2006) Update of human spinal cord reirradiation tolerance based on additional data from 38 patients. Int J Radiat Oncol Biol Phys 66:1446–1449
Kandi M, Hoffmann L, Sloth Moeller D et al (2018) Local failure after radical radiotherapy of non-small cell lung cancer in relation to the planning FDG-PET/CT. Acta Oncol 57:813–819
Käsmann L, Niyazi M, Blanck O et al (2018) Predictive and prognostic value of tumor volume and its changes during radical radiotherapy of stage III non-small cell lung cancer: a systematic review. Strahlenther Onkol 194:79–90
Vestergaard HH, Christensen MR, Lassen UN (2018) A systematic review of targeted agents for non-small cell lung cancer. Acta Oncol 57:176–186
Park KR, Lee CG, Tseng YD et al (2017) Palliative radiation therapy in the last 30 days of life: a systematic review. Radiother Oncol 125:193–199
Nieder C, Angelo K, Dalhaug A et al (2015) Palliative radiotherapy during the last month of life: predictability for referring physicians and radiation oncologists. Oncol Lett 10:3043–3049
Jackson MA, Ball DL (1987) Palliative retreatment of locally recurrent lung cancer after radical radiotherapy. Med J Aust 147:391–394
Montebello JF, Aron BS, Manatunga AK et al (1993) The reirradiation of recurrent bronchogenic carcinoma with external beam irradiation. Am J Clin Oncol 16:482–488
Gressen EL, Werner-Wasik M, Cohn J et al (2000) Thoracic reirradiation for symptomatic relief after prior radiotherapeutic management for lung cancer. Am J Clin Oncol 23:160–163
Kramer GWPM, Gans S, Ullmann E et al (2004) Hypofractionated external beam radiotherapy as retreatment for symptomatic non-small-cell lung carcinoma: an effective treatment? Int J Radiat Oncol Biol Phys 58:1388–1393
Ebara T, Tanio N, Etoh T et al (2007) Palliative re-irradiation for in-field recurrence after definitive radiotherapy in patients with primary lung cancer. Anticancer Res 27:531–534
Cetingoz R, Arikan-Alicikus Z, Nur-Demiral A et al (2009) Is re-irradiation effective in symptomatic local recurrence of non small cell lung cancer patients? A single institution experience and review of the literature. J BUON 14:33–40
Kruser TJ, McCabe BP, Mehta MP et al (2014) Reirradiation for locoregionally recurrent lung cancer: outcomes in small cell and non-small cell lung carcinoma. Am J Clin Oncol 37:70–76
Huh GJ, Jang SS, Park SY et al (2014) Three-dimensional conformal reirradiation for locoregionally recurrent lung cancer previously treated with radiation therapy. Thoracic Cancer 5:281–288
Schlampp I, Rieber J, Adeberg S et al (2019) Re-irradiation in locally recurrent lung cancer patients. Strahlenther Onkol 195:725–733
Poltinnikov IM, Fallon K, Xiao Y et al (2005) Combination of longitudinal and circimferential three-dimensional esophageal dose distribution predicts acute esophagitis in hypofractionated reirradiation of patients with non-small-cell lung cancer treated in stereotactic body frame. Int J Radiat Oncol Biol Phys 62:652–658
Patel NR, Lanciano R, Sura K et al (2015) Stereotactic body radiotherapy for re-irradiation of lung cancer recurrence with lower biological effective doses. J Radiat Oncol 4:65–70
Ren C, Ji T, Liu T, Dang J et al (2018) The risk and predictors for severe radiation pneumonitis in lung cancer patients treated with thoracic reirradiation. Radiat Oncol 13:69
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
C. Nieder, B. Mannsåker, R. Yobuta, and E. Haukland declare that they have no competing interests.
Ethical standards
All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. This retrospective quality of care study did not require approval by the REK Nord research committee, in line with national standards.
Rights and permissions
About this article
Cite this article
Nieder, C., Mannsåker, B., Yobuta, R. et al. Provider decision regret—a useful method for analysis of palliative thoracic re-irradiation for lung cancer?. Strahlenther Onkol 196, 315–324 (2020). https://doi.org/10.1007/s00066-020-01577-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00066-020-01577-0